0A4D.LSE Equillium, Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0A4D.LSE undervalued?
Graham numberThe Graham number of Equillium, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Equillium, Inc. fundamental analysis
No fundamental analysis for Equillium, Inc. yet.
Equillium, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Equillium, Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was…
Full company profileFinancial statements of Equillium, Inc. are not available yet.
Equillium, Inc. dividends
Equillium, Inc. has not paid dividends in the last 4 fiscal years.
Who owns Equillium, Inc.
- Insiders 16.00%
- Institutions 65.82%
- Public & others 18.18%
- Free float 47.9M
Equillium, Inc. company profile
- Company name
- Equillium, Inc.
- Ticker
- 0A4D.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Fiscal year end
- December
- Address
- 2223 Avenida De La Playa, La Jolla, CA, United States, 92037
- Phone
- 858 240 1200
- Website
- equilliumbio.com
About Equillium, Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Equillium, Inc. management
6- Mr. Bruce SteelCo-Founder, CEO & Director · born 1966
- Dr. Stephen Connelly Ph.D.Chief Scientific Officer & President · born 1981
- Ms. Christine Zedelmayer M.B.A., P.M.P.Senior VP & COO · born 1970
- Ms. Penny Tom CPASenior VP of Finance & Principal Accounting Officer
- Mr. Michael MooreVice President of Investor Relations & Corporate Communications
- Dr. Lisette AcevedoVice President of Clinical Development